Back HIV Treatment Experimental HIV Drugs

Experimental HIV Drugs

ASM Microbe 2016: PRO-140 Antibody Injections Maintain Viral Suppression Off ART

Subcutaneous injections of PRO 140, a monoclonal antibody that blocks HIV entry into cells, was well-tolerated and maintained undetectable viral load for more than a year after stopping antiretroviral therapy (ART) in patients with viral suppression, according to a study presented at the ASM Microbe 2016 meeting this week in Boston.

alt

Read more:

FDA Approves Descovy TAF Combination Pill for HIV Treatment, Not Yet for PrEP

The U.S. Food and Drug Administration (FDA) this week approved Gilead Sciences' Descovy, a new combination pill containing tenofovir alafenamide (TAF), which is easier on the kidneys and bones than the older tenfovir disiproxil fumarate (TDF) version. The new coformulation is similar to Truvada, but it has been approved only for use as a component of HIV treatment, not for pre-exposure prophylaxis or PrEP.

alt

Read more:

CROI 2016: Combination Inhibitor BMS-986197 Demonstrates Good Anti-HIV Activity in Early Study

A long-acting bioengineered "combinectin" molecule with a triple mechanism of action demonstrated potent antiviral activity and worked against HIV that developed resistance to any of the 3 separate mechanisms in a laboratory study, and lowered viral load in humanized mice, according to research presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last month in Boston.

alt

Read more:

CROI 2016: Long-Acting MK-8591 Could Be Future Option for HIV Treatment and Prevention

Merck's MK-8591, n investigational antiretroviral agent that maintains drug levels that are able to inhibit HIV up to 6 months after dosing could represent a "paradigm shift" in HIV therapy and prophylaxis, according to research presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016) in Boston.

alt

Read more:

FDA Approves Second TAF-Containing Single-Tablet HIV Regimen

The U.S. Food and Drug Administration (FDA) this week approved Gilead Sciences' new once-daily single-tablet regimen Odefsey, containing the NNRTI rilpivirine (developed by Janssen), emtricitabine, and tenofovir alafenamide or TAF, a new formulation that is easier on the kidneys and bones than the older tenofovir disoproxil fumarate or TDF.

alt

Read more: